An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...

Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

A new obesity drug combining four hormones may outperform Wegovy and Mounjaro. Learn what it means for health, science, and investors.

Ozempic is an FDA-approved medication for people with type 2 diabetes. It’s often prescribed off-label for weight loss — that ...

“GLP-1 drugs don’t just curb appetite – they dull the desire to drink at a metabolic level. With cravings suppressed and ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

Taking advantage of a broken patent system, Big Pharma is making minor tweaks to medications just to keep affordable generics ...

Despite the jump in the number of teens being prescribed Wegovy, it still represents only a small fraction of kids who are living with obesity. Approximately one in 5 children and teens in the U.S.

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

European health officials are warning that the popular weight-loss drugs Ozempic and Wegovy can cause a potentially dangerous eye condition as a side effect. The European Medicines Agency’s safety ...

In 2022, Wegovy was approved for kids 12 and elderly individuals who struggle with obesity. However, the rates surged to 17.3 prescriptions per 100,000 teens in 2025. A Truveta review of 1.3 million ...